SCHEMBL745037

SCHEMBL745037

O=S(=O)(Cl)N1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3937944 0.97 CA1 (0.58)
SCHEMBL417152 0.97 CA1 (0.58)
SCHEMBL1935164 0.93
SCHEMBL2261416 0.85 POLB (0.42)
SCHEMBL22003894 0.85
SCHEMBL1546827 0.74 POLB (0.87)
SCHEMBL347200 0.72 CYP2D6 (0.37)
SCHEMBL1335067 0.71
SCHEMBL5280013 0.71 POLB (0.93)
SCHEMBL29905605 0.71 POLB (0.93)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010115869-A1 PROPOFOL PHOSPHONYL DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS SEPS PHARMA N.V. (BE) 2010-10-14 WO claimed
US-20260109711-A1 MACROCYCLIC SULFONAMIDE MODULATORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2026-04-23 US disclosed
US-12559492-B2 BRAF degraders C4 THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
US-12545669-B2 Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives PFIZER INC. (US) 2026-02-10 US disclosed
US-12486253-B2 Therapeutics for the degradation of mutant BRAF C4 THERAPEUTICS, INC. (US) 2025-12-02 US disclosed
US-20250282762-A1 PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF NOVARTIS AG (CH) 2025-09-11 US disclosed
US-20250276964-A1 Benzisoxazole Derivatives and Uses thereof NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2025-09-04 US disclosed
US-20250241915-A1 COMPOUNDS FOR THE TREATMENT OF BRAF-ASSOCIATED DISEASES AND DISORDERS PFIZER INC. (US) 2025-07-31 US disclosed
US-20250195516-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2025-06-19 US disclosed
EP-3728194-B1 QUINOLINE SULFONAMIDE COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS OTAGO INNOVATION LTD (NZ) 2025-06-04 EP disclosed
WO-1997000872-A1 1,3,8-TRIAZA- AND 3,8-DIAZA-1-OXASPIRO(4,5)DECANE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 1997-01-09 WO disclosed
WO-1996005216-A1 ESTRA-1,3,5(10)-TRIENE DERIVATIVES, METHODS OF PREPARING SUCH COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM JENAPHARM GMBH (DE) 1996-02-22 WO disclosed
US-5457118-A Pyridine derived agents for cardiovascular diseases PFIZER INC. (US) 1995-10-10 US disclosed
EP-0579618-A1 PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES Pfizer Limited (GB) 1994-01-26 EP disclosed
WO-1992017451-A1 PYRIDINE- AND IMIDAZOLE-DERIVED AGENTS FOR CARDIOVASCULAR DISEASES PFIZER LIMITED (GB) 1992-10-15 WO disclosed
EP-0010249-A2 Herbicidal agents, process for their preparation and their use in combating weeds BAYER AG (DE) 1980-04-30 EP disclosed
EP-0010250-A2 Use of Sulfonanilides in inhibition of plant growth BAYER AG (DE) 1980-04-30 EP disclosed
US-4066778-A ANTIBACTERIAL, ANTIPROTAZOA, ANTHELMINTIC CIBA-GEIGY CORPORATION (US) 1978-01-03 US disclosed
US-3976778-A ANTHELMINTIC, BACTERICIDE, ANTIPROTOZOA CIBA-GEIGY CORPORATION (US) 1976-08-24 US disclosed
US-3951958-A VAGINOTROPIC SCHERING AKTIENGESELLSCHAFT (DT) 1976-04-20 US disclosed